Access cutting-edge hematological malignancy treatment through this phase 2 clinical trial at a research site in Morgantown. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Morgantown location
Preparing your pre-screening questions…
Access hematological malignancy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hematological malignancy treatment provided free
Check if you qualify for this hematological malignancy clinical trial in Morgantown, WV
No-Cost Study Care
Local to Morgantown
Convenient for WV residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neutrophils/milliliter) for more than seven days. Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of bacteria. It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive alternative to consider in this prophylactic setting. Eravacycline has activity against MRSA, VRE, and Clostridioides difficile, all of which are common problems in this patient population. It also covers the majority of enteric gram-negative pathogens while also producing satisfactory tissue penetration and adequate plasma concentrations, which has classically been a concern with prior agents. Eravacycline has activity against coagulase-negative staphylococcus, which is a common catheter-related infection in leukemia and HSCT patients. The primary objective will be report the incidence of breakthrough infections during eravacycline prophylaxis for hematologic malignancy patients with prolonged neutropenia.
Sponsor: West Virginia University
Yes, this clinical trial (NCT05537896) has an active research site in Morgantown, WV that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hematological malignancy treatment options in Morgantown, WV, this clinical trial (NCT05537896) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Morgantown research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hematological malignancy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hematological malignancy clinical trials near you to find additional studies recruiting in your area.
See all interstitial cystitis clinical trials recruiting in Morgantown — not just this study.
Browse Interstitial Cystitis Trials in Morgantown →